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Abstract
Objective: To present a wide-ranging review of the literature on bronchopulmonary dysplasia, covering new
definitions, pathophysiology, prevention, treatment, prognosis and progression.
Sources of data: The most relevant articles published on the subject since it was first described in 1967 were
selected from MEDLINE search results.
Summary of the findings: Bronchopulmonary dysplasia is considered one of the primary causes of chronic lung
disease among infants. It is associated with frequent and prolonged hospital admissions, in particular for pulmonary
diseases, with high rates of mortality and alterations to neuropsychomotor development and pondero-statural
growth. Pathogenesis is complex, being primarily influenced by prematurity, infection, supplementary oxygen and
mechanical ventilation. Prevention involves appropriate prenatal care, the prevention of premature delivery,
prenatal corticosteroids, surfactant replacement therapy and protective ventilatory strategies. Treatment of
bronchopulmonary dysplasia patients demands a multidisciplinary team. When indicated, oxygen supplementation
is extremely important. Despite increased risk of morbidity and mortality during the first years of life, long term
progress is favorable in the majority of cases.
Conclusions: Bronchopulmonary dysplasia has been and continues to be studied in great depth with the
objective of identifying its causes and possible prevention and treatment strategies. Controversies remain with
respect of these issues and also about the prognosis of these patients, in particular when the subject is long-term
progress of new bronchopulmonary dysplasia patients.
J Pediatr (Rio J). 2005;81(2):99-110: Bronchopulmonary dysplasia, oxygen therapy, mechanical ventilation,
corticosteroid, prevention, treatment, progression.
0021-7557/05/81-02/99
Jornal de Pediatria
Copyright © 2005 by Sociedade Brasileira de Pediatria
REVIEW ARTICLE
Bronchopulmonary dysplasia
Luciana F. Velloso Monte,1 Luiz Vicente F. da Silva Filho,2
Milton Harumi Miyoshi,3 Tatiana Rozov4
Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung
disease with peculiar clinical, radiological and histological
characteristics. In general, it affects preterm infants
submitted to oxygen therapy and to mechanical ventilation
in the first days of life. Since it was first described in the
1960s, there has been considerable improvement in
perinatal care, such as the widespread use of antenatal
corticosteroids, exogenous surfactant therapy and the
development of new techniques for noninvasive monitoring
and for mechanical ventilation. Such facts have contributed
to the increase in the survival of immature newborns and,
as a consequence, to the higher incidence of BPD.
Approximately 3,000 to 7,000 newborns have been
estimated to suffer from this disease in the USA every
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year. Although the frequency of this disease has not
decreased in the last few decades, the improvements
made to the treatment of newborns with respiratory
failure have minimized its severity. However, BPD is still
extremely important clinically and is also a public health
concern, as it is currently known as one of the major
causes of chronic respiratory diseases among infants,
resulting in frequent hospitalizations with high rates of
mortality, impaired weight and height growth, and
neurodevelopmental disorders.1-3 For these reasons, there
have been many ongoing studies to determine its causes
and find alternatives to its prevention and treatment. The
present study reviews the most relevant aspects related
to the pathophysiology of BPD, in addition to important
issues regarding its prevention, treatment and clinical
follow-up.
Definition
BPD was first described by Northway et al.4 in 1967 as
a chronic lung disease that affected preterm newborns
with respiratory distress syndrome (RDS), or hyaline
membrane disease, submitted to prolonged mechanical
ventilation at high pressure levels and fractions of inspired
oxygen (FiO2). At that time, the disease was classified
into four stages according to its clinical, radiological and
pathological characteristics. The patients presented with
tachydyspnea and room-air hypoxemia, hyperlucent cystic
lesions alternating with strands of radiodensity on the
chest X-ray, cardiomegaly and cor pulmonale, in addition
to metaplasia and pulmonary fibrosis. Most of them were
oxygen dependent for months or even years. In 1969,
Pursey et al.5 described diffuse lung disorders related to
prolonged mechanical ventilation in newborns with
pulmonary disease of several etiologies, including those
who did not have RDS, suggesting that this condition did
not necessarily predisposed to BPD.
In 1979, Bancalari et al.6 defined BPD as respiratory
failure in newborns who required mechanical ventilation for
at least three days and continued oxygen dependence for
over 28 days, showing signs of increased breathing effort
and pulmonary radiological findings. This was the most
widely used criterion in the 1980s and early 1990s.
Nevertheless, improvements in perinatal care in the last
few decades have increased the survival of extremely
preterm infants, especially of those weighing less than
1,000 grams at birth. These patients often depend on
oxygen therapy and/or mechanical ventilation up to 28 days
of life, but they do not present with remarkable pulmonary
involvement. On top of that, many of these patients become
asymptomatic and are weaned from oxygen supplementation
before their hospital discharge. Bearing these findings in
mind, Shennan et al.,7 in 1988, suggested a new definition
with the aim of identifying newborns at higher risk for the
development of chronic lung disorders. The authors
introduced the term chronic lung disease in preterm infants,
regarding it as the persistence of respiratory signs and
symptoms accompanied by pulmonary radiological findings,
with necessity of oxygen supplementation for longer than 36
weeks postconceptional age, which might be a better
predictor of long-term respiratory outcomes.
However, none of these definitions accurately
determines the severity of lung injury. Due to changes in
the epidemiological, clinical and histopathological
characteristics of the disease, a recent workshop has
been held in the USA, organized by the National Institute
of Child Health and Human Development (NICHD) and the
National Heart, Lung, and Blood Institute (NHLBI) in
partnership with the Office of Rare Diseases (ORD), with
the aim of standardizing the terminology, defining severity
criteria and implementing strategies for the prevention
and treatment of BPD.8 In order to avoid terminological
confusion, the consensus conference decided on the use
of bronchopulmonary dysplasia instead of chronic lung
disease, due to the clear distinction of this disease, in
epidemiological, etiopathogenic and prognostic terms,
from other forms of chronic lung diseases that occur in
infants and children. Moreover, new diagnostic and severity
criteria were proposed for BPD. Thus, BPD should be
considered in any newborn that depends on oxygen
supplementation at levels greater than 21% for 28 days
or longer. These patients, according to their gestational
age, must be submitted to diagnostic reassessment and
to disease severity analysis (see Table 1). Radiological
findings, albeit extremely common, were considered to be
inconsistently interpreted, and therefore should not be
used for the definition or evaluation of BPD severity,
according to the consensus.
Incidence
The incidence of BPD is inversely proportional to
gestational age and birthweight. It rarely affects newborns
with over 34 weeks gestational age, although some cases
have been described in full-term infants. Due to
improvements in perinatal care, the incidence of the
severe or classic form of BPD has decreased considerably.
Furthermore, case descriptions vary substantially from
one health center to another, due to the different
populations analyzed, to the lack of standardized
ventilatory strategies for the treatment of acute lung
disease, to the great variability regarding fluid
administration and the care of critically ill newborns and
to the different diagnostic criteria used to define the
disease (Table 2).9-12 In Brazil, Cunha et al.13 found a
DBP incidence of 26.6% during evaluation of 124 infants
with birth weights under 1,500 g who survived more than
28 days during years 2000 and 2002.
Pathophysiology
BPD is a multifactorial disease (Figure 1). These
various factors are believed to act in a cumulative and
synergic fashion, causing inflammation and lung injury.8
Injury to the lung tissue results in fibrosis and in an
abnormal maturation process.
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Factors associated with lung injury
Preterm birth: the prevalence of BPD is inversely
proportional to gestational age at birth. Lung immaturity is
therefore one of the most important factors in the
etiopathogenesis of the disease. BPD represents the response
of immature lungs to acute lung injury induced by mechanical
ventilation, oxygen, and other factors. Antioxidant systems
develop during the last trimester of gestation and, therefore,
antioxidant enzyme activity is relatively deficient in preterm
infants. In addition, these patients also have lower
antiprotease levels. These are some of the reasons why it
is difficult to control inflammation in these patients. Moreover,
the regulation of repair mechanisms is impaired, favoring
the development of fibrosis in the affected segments.
Nevertheless, it is still unclear how lung immaturity interferes
with the inflammation x repair process, producing
irreversible lesions.1,2,14
Oxygen: Oxygen-induced lung injury is caused by the
overproduction of toxic radicals, such as superoxide,
hydrogen peroxide and free radicals. As previously reported,
newborns, especially preterm ones, are more susceptible to
these lesions because antioxidant systems (e.g.: catalase
and superoxide dismutase) are not fully developed yet. The
active oxygen metabolites cause extensive tissue damage
due to enzyme oxidation, protease inhibition, DNA synthesis
inhibition, decrease in surfactant synthesis, and lipid
peroxidation, in addition to acting as chemotactic factors for
inflammatory cells.1,2,14
Mechanical ventilation: the two major factors related to
ventilator-induced lung injury are alveolar instability, which
Table 1 - Diagnostic criteria and classification of BPD severity8
PMA = postmenstrual age; BPD = bronchopulmonary dysplasia; FiO2 = fraction of inspired oxygen; CPAP = continuous positive
airway pressure; MV = mechanical ventilation.
* On time of reassessment, the oxygen requirement and/or assisted ventilation (nasal CPAP or MV) should not reflect an “acute”
event, but should rather reflect the infant’s usual daily therapy for several days. Besides that, it is recommended to perform a
physiologic test confirming the real oxygen requirement and/or assisted ventilation. This test remains to be defined.
† Whichever comes first.
‡ There are no reports on how FiO2 is measured.§ Do not consider patients who requires oxygen and/ or assisted ventilation for treatment of nonrespiratory disease (e.g., central
apnea, diaphragmatic paralysis etc), unless they also develop parenchymal lung disease and respiratory distress.
Newborn in oxygen therapy Gestational age at birth
for at least 28 days < 32 weeks > 32 weeks
Time point of reassessment * 36 weeks PMA 56 days postnatal age
or discharge to home  or discharge to home 
Mild BPD Breathing room air Breathing room air
Moderate BPD Need for FiO2 < 0.30 
 § Need for FiO2 < 0.30 
 §
Severe BPD Need for FiO2 > 0.30 Need for FiO2 > 0.30
and/or CPAP or MV  § and/or CPAP or MV  §
Table 2 - Percent of patients with bronchopulmonary dysplasia
according to birth weight and diagnostic criteria (oxygen
dependence on 28 days of life or on 36 weeks
postconceptional age)10
Oxygen dependence
Birthweight 28 postnatal 36 postconceptional
days age
< 750 g 90-100% 54%
750 - 999 g 50-70% 33%
1,000 - 1,249 g 30-60% 20%
1,250 - 1,499 g 6-40% 10%
Figure 1 - Pathogenesis of bronchopulmonary dysplasia1
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causes atelectasis (atelectrauma), and regional
overdistension of alveoli and airways (barotrauma/
volutrauma). Atelectrauma is an injury produced by repeated
cycles of alveolar collapse and re-expansion during
mechanical ventilation. The development of nonrecruited
areas (atelectasis) is not only a consequence, but also a
cause of lung injury. Some evidence exists that ventilatory
strategies that use low positive end-expiratory pressure
(PEEP) are associated with more pronounced lung injuries
and with less efficient exogenous surfactant therapy.
Therefore, ventilation should target the alveolar recruitment,
increasing functional residual capacity. Thus, the lung is
protected from atelectrauma, high oxygen concentrations
may not be required and consequently pulmonary damage
is reduced. Volutrauma is the injury associated with
overdistension of pulmonary structures due to the use of
large tidal volumes during mechanical ventilation. This
causes pulmonary damage because of the stretching of
alveoli, airways, basement membrane and pulmonary
capillary endothelium. Therefore, capillary permeability is
increased and causes fluid, protein, and blood to leak into
the airways, resulting in edema and inflammation.
Additionally, the rupture of the alveolar-capillary barrier
caused by volutrauma may allow inflammatory mediators
and bacteria to enter the bloodstream and produce systemic
inflammatory reaction and infection in other organs.
Atelectrauma and volutrauma synergically contribute to
pulmonary damage. Nowadays, it is known that insufficient
PEEP (predisposing to atelectrauma) and the use of large
tidal volumes are the major causes of acute lung injury
induced by mechanical ventilation. Barotrauma is the lung
injury produced by high pressures during mechanical
ventilation. Studies with experimental models using high
ventilatory pressures without large tidal volumes caused
relatively less lung injury. Currently, it is believed that
pressure alone is not a major factor for the development of
lung injury. 2,8,14,15
Infection: There is evidence that prenatal and postnatal
infection may contribute to the development of BPD due to
the release of inflammatory mediators and to the influx of
inflammatory cells into the lung. Some studies correlate the
occurrence of chorioamnionitis with the development of
BPD. Others suggest the association of BPD with Ureaplasma
urealyticum infection, but it has not been confirmed whether
this is a causal relationship. In addition to causing the
release of proinflammatory mediators, lung infection, either
congenital or nosocomial, may result in the necessity for
ventilatory support, which deteriorates pulmonary damage
even further.1,14-17
Patent Ductus Arteriosus (PDA): PDA causes an increase
in pulmonary blood flow and interstitial edema, reducing
lung compliance and increasing airway resistance. This may
result in a more aggressive and prolonged ventilatory
strategy, elevating the risk for the development of BPD.1
Genetic factors: There may be a genetic predisposition
to the development of BPD. The mechanism has not been
elucidated yet, but it may be related to the lung repair
process, with higher or lower stimulation to the reconstruction
of normal lung tissue or to the proliferation of fibroblasts and
fibrosis. It has been suggested that pulmonary growth
regulatory genes undergo the action of inflammatory
mediators found in the affected lung (e.g.: transforming
growth factor - TGF-ß), probably stimulating the gene
expression of mediators that predispose to the development
of fibrosis.1,8
Malnutrition and vitamin A deficiency: the preserved
nutritional status and vitamin A contribute to the
differentiation, regeneration and reepithelization of lung
tissue, and some authors suggest the association of these
components with BPD.1,18,19
Inflammation is the end product of the factors that
produce lung injury. The inflammatory process results from
injury to the respiratory epithelium and to the pulmonary
capillary epithelium, causing the release of proinflammatory
mediators and chemotactic cytokines. There is an influx of
inflammatory cells, especially granulocytes, which
potentiates the inflammatory reaction by producing more
cytokines (interleukin-8, macrophage inflammatory protein-
1, TGF-ß, among others) and release of enzymes (e.g.:
elastase). These substances increase vascular permeability,
which contributes to interstitial, alveolar and airway edema.
One should recall that pulmonary circulation not only receives
the entire cardiac output but also harbors a large reservoir
of neutrophils. Therefore, the lung contributes to the
circulation of cells and inflammatory mediators through the
whole body.1,14,15,20,21
Healing
There are two outcomes for the inflammatory process:
repair of pulmonary structures with restoration of normal
lung function, or fibrosis, causing impairment of respiratory
function. The outcome to be achieved depends on several
factors, such as nutritional status, inflammatory mediators,
genetic factors, among others, as previously described.
Lung repair consists of reepithelization and reconstruction
of the lung parenchyma. Type II pneumocytes play a key
role by differentiating in type I pneumocytes, replacing the
damaged cells. In fibrosis, alveolar macrophages are
regarded as the main cells in charge of releasing cytokines
that lead to the proliferation of fibroblasts and collagen
deposition. There seems to be a variable spectrum between
these two processes in the same patient in different
pulmonary regions, which may explain the great clinical
variability of the disease.1,8,15
Lung development and BPD
A series of perinatal events have been associated with
the occurrence of BPD, mainly the development of the
respiratory system. Lung development is completed in the
first years of life, so even full-term newborns experience the
alveolarization of lung tissues in an intense manner. Preterm
births may occur before the canalicular period of lung
development, which comprises from the 17th to the 24th
week of gestation, or during saccular and alveolar periods
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(after the 25th week). In the canalicular period, the
maturation of lung airways occurs, followed by the
development of respiratory units, which will be mature in
the saccular and alveolar stages, preparing the lung for gas
exchange. Injury during the development of the lung
parenchyma may alter the alveolarization process, causing
alveolar simplification. Thus, BPD represents a rupture in
the normal development and repair of lungs in response to
acute lung injury.1,8,14,15
Clinical picture
The clinical picture encompasses respiratory symptoms
associated with oxygen dependence and radiological findings
in newborns, usually preterm ones, submitted to mechanical
ventilation. Pulmonary auscultation may be poor, and just
tachydyspnea may be observed. In more severe cases,
hypoxemia may be accompanied by hypercapnia. Many
patients show chest deformity, different levels of
tachydyspnea and less tolerance to physical exercises.
Cough and wheezing are frequent. Symptoms vary
considerably and depend on the severity of BPD.1,15
Radiological findings
Radiological findings range from pulmonary hyperinflation
with thickening of bronchi and atelectasis to the presence of
radiopaque images of fibrosis, large cysts, and interstitial
emphysema. The pulmonary artery trunk may be evident
due to associated pulmonary hypertension and, in extremely
severe cases, cardiomegaly may be observed. Over 90% of
BPD patients have abnormalities at high-resolution computed
tomography.1,15,22
Pathological aspects
In the pre-surfactant era pathological findings of BPD
were predominantly characterized by chronic inflammation
and fibrosis of the lung parenchyma, besides squamous
epithelial metaplasia and airway smooth muscle hypertrophy.
Since lung injury and the clinical picture were more severe,
the involvement of the cardiovascular system was also more
pronounced, with proliferation of the tunica intima,
hypertrophy of the muscle layer and of the right ventricle
(cor pulmonale). This classic BPD is quite uncommon
nowadays, due to the use of antenatal corticosteroids, to
neonatal surfactant replacement, to less aggressive
ventilatory strategies and to the improved support care of
preterm infants. However, it may still be observed in
patients who require aggressive and prolonged ventilatory
support, as in severe meconium aspiration syndrome,
pulmonary hypoplasia associated with diaphragmatic hernia
and congenital pneumonia accompanied by pulmonary
hypertension, among other disorders.
From the 1990s on, with the improvements in perinatal
care, the survival of extremely preterm infants has increased.
The lungs of these patients are in the canalicular or saccular
stage of development, as previously described. At birth,
even in the presence of few injuries, there is discontinuation
or inhibition of normal lung development and growth. An
interference is believed to occur in the indicative processes
of lung development, impairing terminal maturation and
the course of alveolarization, probably due to secondary
septal defect. Then, one may observe simplification of
distal areas, with a smaller number of alveoli. There is
less fibrosis, more elastic tissue and less injury to the
airways. In addition, the development of pulmonary
microvasculature is inhibited, which contributes to the
increase in vascular resistance. This picture is currently
known as new BPD (Table 3).1,8,14,15
Lung function
Abnormal findings regarding lung function have different
intensity and include:
 increase in airway resistance and restriction of airflow,
leading to bronchial hyperresponsiveness;
 increase in breathing effort;
 decrease in lung compliance due to fibrosis,
hyperinflation, and atelectasis;
 increase in residual volume and decrease in functional
residual capacity;
 hypoxemia, aggravated by factors, such as sleep,
agitation, feeding and infections;
 hypercapnia in more severe cases.
The persistence of these functional problems varies,
as described further ahead.1,22-24
Prevention of BPD
Prevention of preterm birth, with adequate prenatal
care, is the major form of prevention of BPD.2,8,14 Among
other preventive measures, we highlight the following:
Corticosteroid therapy
Antenatal use: the beneficial effects of the antenatal
use of cort icosteroids is wel l  establ ished. The
administration of this drug to mothers before preterm
delivery reduces the incidence of RDS, peri/intraventricular
hemorrhage and neonatal mortality. Corticosteroids seem
to increase the amount of antioxidant enzymes and
regulate the differentiation of several fetal tissues,
preparing the conceptus for preterm birth. The effects of
this drug seem to be enhanced when, combined with
maternal corticosteroid therapy, preterm newborns receive
exogenous surfactant replacement immediately after birth,
which considerably reduces the need for aggressive
ventilatory support. Although not confirmed by controlled
studies, the use of steroids reduces the incidence and
severity of BPD. Thus, the use of corticosteroids should be
considered in all expectant mothers who go into premature
labor between 24 and 34 weeks of gestational age.
Postnatal use: in the literature, the recommendations
for systemic corticosteroid therapy in the postnatal period
Bronchopulmonary dysplasia  Monte LFV et alii
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are extremely controversial and vary across different health
centers.25-27 There is some evidence that the inflammatory
process plays a crucial role in the pathogenesis of BPD. This
has allowed for the use of therapies that are able to reduce
or regulate the pulmonary inflammatory process as an
attempt to reduce the incidence or severity of BPD.
Corticosteroid therapy reduces the inflammatory process,
edema and fibrosis, in addition to inducing bronchodilation.
The therapy quickly improves lung function, allowing for the
discontinuation of mechanical ventilation. For this reason,
corticosteroids have been considered a good alternative to
the prevention and treatment of BPD. Studies have shown
that systemic corticosteroids actually reduce the incidence
of BPD and allow for earlier extubation. However, long-term
neurological disorders have been observed in these patients,
especially with the early use of dexamethasone in high
doses. A recent meta-analysis28 has concluded that the use
of corticosteroids in preterm newborns, despite the above-
mentioned benefits, did not improve mortality rates or the
length of hospital stay. Short-term benefits may not outweigh
the long-term severe risks of postnatal corticosteroid therapy,
especially with regard to neurological disorders. Therefore,
the systemic administration of corticosteroids in the neonatal
period should be limited to special situations and should only
be initiated after informed consent from the parents.26,28-32
Nevertheless, there are still controversies about postnatal
administration of corticosteroids.33 Its use is considered for
preterm infants who depend on mechanical ventilation for
over seven days and whose radiological findings are
compatible with BPD, meeting the following criteria:
 necessity of FiO2 greater than 0.40 and mean airway
pressure greater than 10 cmH2O;
 clinical and radiological evidence of recurrent atelectasis,
recurrent pulmonary edema refractory to diuretics or
presence of bronchial hyperresponsiveness (wheezing,
pulmonary hypersecretion).
It is important that clinical intercurrent events be
identified and treated before initiating corticosteroid
therapy, since they may contribute to the deterioration of
respiratory symptoms. These intercurrent events include:
PDA with hemodynamic repercussion, air leak syndrome,
infectious process, inefficient respiratory impulses
(immaturity of the respiratory center or central nervous
system injury), metabolic disorders, and malnutrition.
We recommend the intravenous or oral administration
of dexamethasone in the following doses: 0.15 mg/kg/day
every 12 hours for 3 days; then, 0.10 mg/kg/day every 12
hours for 3 days, and finally, 0.05 mg/kg/day every 12
hours for 3 days. If there is a positive response, with
reduction of ventilatory parameters (pressure and FiO2)
after the initial doses (first 3 days), the treatment can be
resumed. If the response is not satisfactory on the first
days, corticosteroid therapy must be discontinued. On top
of that, even if patients meet the criteria for corticosteroid
therapy, repeated administration of the drug must be
avoided, seeking to find alternatives to manage the
respiratory symptoms.
With regard to the use of inhaled corticosteroids in
newborns, some authors have reported improvement in
extubation rate and lower demand for systemic
corticosteroid therapy. However, there are few studies on
the use of inhaled corticosteroids for the prevention of
BPD, thus hindering any conclusions.30,34-39
Table 3 - Characteristics of new bronchopulmonary dysplasia and old or classic bronchopulmonary dysplasia
Type Characteristics
New bronchopulmonary dysplasia Less smooth muscle hypertorphy
Less fibrosis
Less severe squamous metaplasia
Small number and increased diameter of alveoli (septation defect?)
Dysmorphic pulmonary microvasculature
Increase in elastic tissue
Classic bronchopulmonary dysplasia Metaplasia of the respiratory epithelium
Smooth muscle hypertrophy
Significant fibrosis
Large vascular modifications
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Surfactant therapy
Exogenous surfactant therapy causes a more
homogeneous alveolar recruitment, stabilizes terminal
airways, reducing the occurrence of atelectasis and helping
to reduce ventilatory parameters. In extremely preterm
infants, there have been advantages of the prophylactic use
(before two hours of life) over the therapeutic use for the
reduction of mortality and of the incidence of BPD. Even
though the use of exogenous surfactant did not reduce the
incidence of BPD, its severity may have been reduced.2
Ventilatory strategies
The aim of mechanical ventilation should include the
reduction of lung injury by the recruitment of collapsed
areas and improvement of the functional residual capacity,
without causing overdistension of already recruited areas.
This way, one tries to minimize atelectrauma and
barotrauma/volutrauma. Several ventilatory strategies
aimed at the reduction of lung injury and consequently of
BPD have been described, such as: conventional ventilation
using lung protection strategies (low tidal volumes -4 to
6 ml/kg, improvement of PEEP and permissive
hypercapnia), prone position, nasal continuous positive
airway pressure (CPAP) and high-frequency ventilation.
However, so far, controlled studies that used these
strategies have not clearly shown reduction in the incidence
of BPD. Moreover, permissive hypercapnia needs to be
further investigated in preterm infants, due to the possible
risk of central nervous system injury.2,8,14,40,41
Vitamin A
Vitamin A acts on the differentiation and maintenance of
the integrity of the respiratory epithelium. Its deficiency
leads to inhibition of the alveolarization process and to the
reduction in mucociliary transport with increase in squamous
metaplasia. Based on these data, some studies have shown
a reduction in the incidence of BPD in newborns at risk who
receive high doses of vitamin A.1,18,19
Inhaled nitric oxide
Nitric oxide is a potent vasodilator and has been used
by inhalation during mechanical ventilation with the aim
of reducing pulmonary shunt and inflammation. Several
studies have been carried out with early use of nitric oxide
in low doses in preterm newborns with pulmonary
hypertension for the prevention of BPD. Results have
been inconclusive so far.8
Superoxide dismutase
Based on the evidence that preterm infants are deficient
in endogenous antioxidant systems and that oxygen free
radicals play a key role in the etiopathogenesis of BPD,
several studies have used antioxidant therapy, especially
superoxide dismutase, for the prevention of BPD. Studies
with experimental models have described beneficial effects
of the tracheal administration of recombinant human
superoxide dismutase, reducing the risk of hyperoxia-
induced injury. Thus, the use of this drug may probably
play a role in the prevention of BPD. Further studies are
necessary because results are still controversial.2,8,42,43
Fluid restriction
Some studies revealed that a mild fluid restriction in
extremely preterm infants may reduce the incidence of BPD,
since pulmonary edema is important in the pathophysiology
of the disease.2
Treatment
The clinical follow-up of BPD patients should preferably
be made by a multidisciplinary team, including neonatologist
and other pediatric subspecialties, such as pulmonology,
cardiology, ophthalmology and neurology, besides
physiotherapist, nutritionist, speech therapist and
occasionally other professionals. Treatment should be on a
case-by-case basis, due to the different clinical
manifestations and severity. The aims of the treatment are
shown in Table 4.1,2,8,10,44
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 Promote the control of symptomatology
 Keep normal activity levels
 Ensure adequate somatic and neuropsychomotor development
 Keep the pulmonary function as normal as possible
 Minimize the disease exacerbations
 Prevent and intervene early in respiratory infections
 Avoid drugs side effects
 Try to maintain the patient at home
Table 4 - Aims of bronchopulmonary dysplasia treatment
Oxygen therapy: one of the mainstays of the treatment
of BPD patients is the maintenance of appropriate arterial
oxygen levels. Hypoxemia is the main cause of cardiovascular
disorders (pulmonary hypertension and cor pulmonale), in
addition to interfering with weight gain and with brain
development in BPD patients. If left untreated, hypoxemia
is associated with a higher risk for sudden death and
episodes of apnea in these infants.10,24 Oxygen should be
preferably supplemented by nasal cannula in order to
maintain the oxyhemoglobin saturation levels between 92
and 95%. In patients with cor pulmonale, higher values,
between 95 and 96%, are recommended. Although there is
some controversy about the best desirable oximetry level
for BPD patients, these values should be kept stable during
feeding sleeping/wake cycle, thus avoiding intermittent
supplementation.10,24
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Nievas et al.,10 in 2002, suggested an algorithm for
oxygen supplementation in BPD (Figure 2). Initially, the
requirement for oxygen is evaluated in alert patients.
Pulse oximeter is used to measure oxygen saturation in an
alert patient, every 2 or 3 weeks, after breathing room air
for ten minutes. If saturation is equal to or greater than
92% (or 95%, if cor pulmonale), oxygen supplementation
may be discontinued during wake periods, but kept during
sleep periods. After that, oxygen saturation is measured
during sleep, preferably using equipment that can record
oximetry during the night.23 Oxygen therapy should be
withheld when the above-mentioned levels have been
achieved. In case of low weight gain at any of the stages
described above, despite a good acceptance of hypercaloric
diet, full-time oxygen therapy should be restarted, since
this is a strong sign of intermittent episodes of remarkable
hypoxemia. If oxygen supplementation is still necessary
for several months after discharge from the neonatal ICU,
attempts should be done to identify coexisting conditions
that might be worsening or mimicking BPD, such as:
untreated gastroesophageal reflux, episodes of
microaspirat ion secondary to cr icopharyngeal
incoordination, undiagnosed congenital heart disease,
among others.1,2,10,24
We recommend maintaining oxygen supplementation
via nasal cannula until medications, such as diuretics, can
be discontinued, and until the patient is clinically stable,
with oxygen saturation equal to or greater than 93%
throughout the day. Discontinuation of nighttime oxygen
therapy often occurs after of daytime supplementation.
Diuretics: some patients also present with recurrent
pulmonary edema or impaired cardiac function. In these
Figure 2 - Oxygen therapy algorithm in bronchopulmonary dysplasia10
* Discontinue O2 only after withdrawal diuretics and corticosteroids.† If inadequate weight gain (< 15-30 g/day): restart O2 awake/ asleep.
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situations, the use of diuretics, mainly furosemide, is
recommended, since some authors believe that, besides the
diuretic effects, this drug has a direct effect on the lungs,
improving compliance and airway resistance. However,
special attention should be paid to the occurrence and
correction of side effects, such as hydroelectrolytic disorders,
hypercalciuria, nephrocalcinosis, among others. Short-term
treatment is efficient in controlling pulmonary edema, but
the efficacy of prolonged use of diuretics is
controversial.1,2,10,24,45,46 Thus, furosemide should be
considered in cases of recurrent and symptomatic pulmonary
edema, and to allow a higher fluid intake with the aim of
increasing energy intake. An intravenous or oral initial dose
of 1 to 2 mg/kg may be recommended twice a day. The use
of diuretics should be discontinued when the patient shows
improvement of pulmonary symptoms. In the cases in which
diuretics have to be maintained for long periods, we
recommend combining hydrochlorothiazide and
spironolactone in the dose of 2 to 4 mg/kg/day or the use
of furosemide on alternate days, in order to minimize
adverse effects. The use of diuretics does not bring any
evident benefits to patients older than six months, except
if there are additional indications (nephrocalcinosis, cor
pulmonale).
Corticosteroids: once BPD is established, inhaled
corticosteroids are recommended (pressurized metered-
dose inhaler with spacer device) for the management of
bronchial hyperresponsiveness.1,2,10 We recommend the
use of inhaled corticosteroids in patients with a more
pronounced involvement of respiratory dynamics and with
clearer clinical and radiological signs of lower airway
obstruction. In this case, we recommend metered-dose
inhalers coupled to valved spacers with an attached face
mask. Low doses should be used for relatively long periods
(at least six months of continuous use).
Bronchodilators: inhaled bronchodilators (administered
via metered-dose inhaler with spacer device) are
recommended for the management of respiratory symptoms
(cough, wheezing) when there is clinical and/or functional
evidence of good response. It is widely known that BPD
causes airway smooth muscle hypertrophy; therefore, most
patients may benefit from the use of these drugs.1,2,10,24,47
The use of oral bronchodilators should be avoided, due to
the high risks of side effects.
Nutrition: several factors contribute to malnutrition in
BPD patients. Among these factors, some of the most
important include high energy expenditure, due to the
increase in breathing effort, disorders related to glucose
and lipid metabolisms, due to chronic hypoxemia, and lower
food intake. The use of a hypercaloric diet (around 110 to
150 kcal/kg/day) is recommended with supplements rich in
medium-chain triglycerides, and some carbohydrate
restriction for those patients who retain carbon dioxide. In
our setting, we may use supplementation with foods
containing canola oil or sunflower oil, which are inexpensive.
It should be underscored that other causes of poor weight
gain may be present, such as hypoxemia, anemia,
gastroesophageal reflux, congenital heart disease, and
swallowing dysfunction, among others. These problems
should be investigated and treated as early as
possible.1,2,10,24,42,48
Immunization strategies: BPD patients are affected
by recurrent respiratory tract infections. In addition to
standard immunizations, these patients should receive
pneumococcal and annual influenza vaccines. Also, there
exists a great risk of infection by the respiratory syncytial
virus (RSV) in preterm infants compared to full-term
newborns. Several studies have shown that prophylaxis
with immunoglobulin against RSV reduces the risk of
hospitalization and the severity of RSV infections.
Currently, the American Academy of Pediatrics49
recommends the use of intravenous RSV immunoglobulin
or preferably intramuscular RSV monoclonal antibody
(palivizumab) during the fall and winter seasons (when
the incidence of RSV is higher) in BPD patients younger
than two years of age in the following cases:
 patients on oxygen therapy; and
 patients who have required treatment for BPD within six
months before the RSV season.
These patients should receive palivizumab during the
fall and winter months in five intramuscular doses of
15 mg/kg, once a month. The use of palivizumab is
contraindicated in infants with cyanogenic congenital
heart disease.1,2,10,50 Nowadays, prophylaxis against
RSV is not possible in public institutions, as this treatment
is not covered by the Brazilian Ministry of Health. Despite
the good results obtained in the USA, there are no studies
in Brazil about the potential reduction in treatment costs
when this kind of prophylaxis is used.
Management of pulmonary hypertension and cor
pulmonale: oxygen administration is the most important
therapy for the relief of pulmonary hypertension, since
cardiovascular disorders are secondary to pulmonary
disorders. As additional treatment, the following medications
may be used: diuretics, calcium channel blockers and nitric
oxide, among others.1
Criteria for hospital discharge
The following criteria have been suggested for the
hospital discharge of infants with BPD:
 oxyhemoglobin saturation around 95% in a stable or
reducing oxygen flow rates for at least two weeks;
 satisfactory weight gain;
 absence of apneic episodes at least in the last two
weeks;
 no need to change drug therapy in the last week;
 possibility of returning for outpatient care in 48 to 72
hours;
 parents feel confident and comfortable in performing
infant care tasks, including the use of oxygen and/or
handling of gastric tube, in specific cases, in addition to
showing qualification for the detection of signs of
deterioration and on how to proceed in case of emergency.
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A home visit should be made before the discharge by
the healthcare team in order to check the required
equipment and to evaluate the knowledge of the people
who will take care of the infant. It is also important to
assess the familys socioeconomic conditions, housing
conditions, access to telephone, transportation and
proximity to referral hospitals.1,3,24
Prognosis and outcome
The prognosis varies according to the severity of the
disease. Morbidity and mortality rates are higher in the
first year of life, decreasing in subsequent years.1,10,22-24
Lungs: BPD patients show higher pulmonary morbidity
in their lives, especially in the first two years of life. This
characteristic may persist into adulthood. Approximately
50% of very-low-birthweight infants have recurrent
wheezing episodes and 33% still show these symptoms at
preschool age. It has been reported that the risk of severe
wheezing is minimized by 10% every additional week of
gestation. The risk for recurrent respiratory symptoms
increases if the patient has siblings, family history of
atopic disease or tobacco exposure, which is why smoking
among family members is strongly discouraged. In addition
to a greater risk for the development of respiratory
symptoms, very-low-birthweight infants with BPD have a
50% hospital readmission rate, twenty times higher than
that observed in full-term infants. The main reason for
hospital admission is lower respiratory tract infection,
especially of viral etiology, which emphasizes the
importance of the previously described immunization
strategies. With regard to the lung function abnormalities
that were previously mentioned, patients have airway
obstruction disease with increased airway resistance and
air trapping, mainly in the first two years of life. These
disorders are observed even in asymptomatic patients,
but to a lesser degree. We may also observe chest
deformity with more or less intensity. The functional
residual capacity tends to normalize throughout the 12th
to 24th month of life. Lung compliance is only 35-50% of
normal range at 2 to 4 months of life. At 10 months of age
reaches 60%, and returns to baseline values in the third
year of life. Residual volume improves slowly and may
normalize only during the 8th and 10th year of life,
whereas airway resistance may persist at high levels into
adulthood. It is estimated that around 50% of these
patients have exercise-induced respiratory symptoms.
Lung growth, with the development of new gas exchange
units, is believed to occur up to the age of eight years.
Oxygen dependence is therefore reversible in most
patients. Apparently, the functional impact of these
disorders is not severe.1,10,22-24,51
Heart: electrocardiographic evidence of right ventricular
hypertrophy has been reported in 50% of school-aged
children with BPD. In adolescents and in young adults,
cardiovascular disorders are rarely observed.22
Growth: in general, infants reach the height growth
curve at around 18 months of life, but their catch-up may
occur up to 10 years of life. According to short-term follow-
up studies, there has been weight and height deficiency in
infants with BPD in comparison to infants without BPD.
Long-term developmental studies have not confirmed this
difference in children aged 8 to 10 years. Currently it is
considered that the poor growth may be related to factors
such as low-birthweight and preterm birth rather than to
BPD.22-24
Development: the frequency of neurological disorders
in children who had BPD ranges from 0 to 60% at 24
months of life. This high variability shows the discrepancies
related to the definition that was used, to different
socioeconomic backgrounds, and to different perinatal
care practices, in addition to the variable severity of the
disease. It is widely known that patients with severe BPD,
especially those who require prolonged mechanical
ventilation and systemic corticosteroid therapy, have a
less satisfactory outcome. Despite cognitive, sensory,
motor and speech disorders, infants often improve with
age. Therefore, the neurological follow-up of BPD patients
is of paramount importance.23,52
One should recall that most long-term follow-up studies
include BPD patients from the pre-surfactant era, whose
disease severity is greater. So far, few data exist on the late
prognosis of patients belonging to the new BPD group.
Conclusion
BPD has been extensively investigated in an attempt to
identify its causes and possibilities of prevention and
treatment. There are, however, controversies over these
issues and also over the prognosis of these patients,
especially with regard to the late development of new
BPD. The identification of strategies for the prevention and
treatment of BPD is a major priority. It constitutes a
promising and wide field to future studies.
Finally, the importance of a follow-up of BPD patients
by a multidisciplinary team should be highlighted. In our
setting, the treatment of patients from underprivileged
socioeconomic backgrounds is extremely difficult, due to
their precarious housing conditions, large number of
people sharing the same household, poor access to health
centers and hospitals, lack of money to buy food and
medications, among other factors. In this case, it is
important that healthcare professionals from different
fields work together so as to improve growth and
development and provide a better quality of life to these
patients and their families.
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